Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer.

OBJECTIVE In Japan, flutamide had been commonly used as second-line alternative antiandrogen hormonal therapy for metastatic castration-resistant prostate cancer that relapses after initial hormone therapy before new androgen pathway inhibitors became available. In this study, we attempted to identify predictive factors for efficacy of alternative antiandrogen as second-line hormone therapy. METHODS We identified consecutive 65 patients with metastatic castration-resistant prostate cancer who were treated with alternative antiandrogen as second-line hormonal therapy (bicalutamide to flutamide). All patients were treated with combined androgen blockade initially. We analyzed correlations between progression-free survival of alternative antiandrogen and clinicopathological characteristics, including patients' ages, initial prostate-specific antigen levels, prostate-specific antigen levels at flutamide induction, Gleason scores, T stage, N stage, extent of disease grades on bone scan and previous duration of prostate cancer response to combined androgen blockade. RESULTS In univariate analysis, T stage, N stage and previous duration of response to combined androgen blockade were correlated with shorter progression-free survival. We found four significant risk factors for shorter progression-free survival in multivariate analysis: initial prostate-specific antigen level, clinical N stage, extent of disease grades and previous duration of response to combined androgen blockade. CONCLUSIONS Initial prostate-specific antigen, N stage, extent of disease grades on bone scan and previous duration of response to combined androgen blockade were the significant predictors for efficacy of alternative antiandrogen as second-line hormone therapy in patients with metastatic castration-resistant prostate cancer. These findings might support that decision-making of when to start the new androgen receptor pathway inhibitors.

[1]  T. Matsuda,et al.  Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. , 2014, Japanese journal of clinical oncology.

[2]  H. Akaza,et al.  Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. , 2012, Asian journal of andrology.

[3]  Seung Ok Yang,et al.  Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade , 2011, Korean journal of urology.

[4]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European Urology.

[5]  F. Saad,et al.  Guidelines for the management of castrate-resistant prostate cancer. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[6]  E. Higashihara,et al.  Alternative antiandrogen therapy in patients with castration‐resistant prostate cancer: A single‐center experience , 2010, International journal of urology : official journal of the Japanese Urological Association.

[7]  H. Akaza,et al.  Combined androgen blockade with bicalutamide for advanced prostate cancer , 2009, Cancer.

[8]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[9]  Tomohiko Ichikawa,et al.  Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. , 2008, The Journal of urology.

[10]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Nishimura,et al.  Effects of flutamide as a second‐line agent for maximum androgen blockade of hormone refractory prostate cancer , 2007, International journal of urology : official journal of the Japanese Urological Association.

[12]  Y. Mizutani,et al.  Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first‐line hormonal therapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[13]  T. Namiki,et al.  Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men , 2006, BJU international.

[14]  H. Miyake,et al.  Clinical outcome of maximum androgen blockade using flutamide as second‐line hormonal therapy for hormone‐refractory prostate cancer , 2005, BJU international.

[15]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[16]  P. Walsh,et al.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997 .

[17]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.

[18]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.